StockData
Acurx Pharmaceuticals, Inc. logo

Acurx Pharmaceuticals, Inc. (ACXP) stock

ACXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.96−0.03 (-2.54%)

Close on Nov 13, 2026Market cap $5.06MP/E –Yield –

Earnings

Acurx Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2025
–
EPS, Q1 FY2025
-$0.11
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Acurx Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2025ended Mar 31, 2025May 13, 2025before the open––-$0.11Release
Q4 FY2024ended Dec 31, 2024Mar 18, 2025before the open––-$0.16Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024before the open––-$0.17Release
Q2 FY2024ended Jun 30, 2024Aug 9, 2024before the open––-$0.26Release
Q1 FY2024ended Mar 31, 2024May 15, 2024before the open–––Release
Q4 FY2023ended Dec 31, 2023Mar 18, 2024after the close––-$0.37Release
Q3 FY2023ended Sep 30, 2023Nov 14, 2023after the close––-$0.24Release
Q2 FY2023ended Jun 30, 2023Aug 14, 2023before the open––-$0.28Release
Q4 FY2022ended Dec 31, 2022Mar 16, 2023before the open––$0.28Release
Q3 FY2022ended Sep 30, 2022Nov 14, 2022before the open––-$0.32Release
Q2 FY2022ended Jun 30, 2022Aug 15, 2022after the close––-$0.26Release
Q1 FY2022ended Mar 31, 2022May 11, 2022before the open––$0.26Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Acurx Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Acurx Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Acurx Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Acurx Pharmaceuticals, Inc. Announces up to
    News
  2. Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm
    News
  3. Inc. Announces Reverse Stock Split
    News
  4. /C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ PR Newswire
    News
  5. Acurx Pharmaceuticals, Inc. Reports First Quarter Results
    Results
  6. Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
    Results
  7. Inc. Announces $1.1 Million Registered Direct Offering
    News
  8. Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    News
  9. Acurx Pharmaceuticals, Inc. Reports Third Quarter
    Results
  10. Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024
    Results
  11. Acurx Pharmaceuticals, Inc. Reports First Quarter
    Results
  12. Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
    Results
  13. Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results
    Results
  14. Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
    News
  15. Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection
    News

See a number that looks wrong?